Background: Hidradenitis suppurativa (HS) has been previously associated with greater rates of major adverse cardiac events (MACEs) compared to the general population. This study aims to better elucidate the association between HS, MACEs, and other cardiovascular diseases. Methods: We utilized TriNetX, a global database of electronic health records, to conduct a retrospective cohort study. HS patients were matched on demographic and cardiovascular disease risk factors to both healthy and psoriasis groups as controls. Results: After adjusting for cardiovascular disease risk factors, HS patients had a relative risk (RR) (95% CI) of 2.06 (1.83–2.32) for myocardial infarction, 1.62 (1.44–1.82) for ischemic stroke, 2.21 (2.04–2.40) for heart failure, 1.95 (1.84–2.07) for MACEs, and 2.57 (2.34–2.83) for all-cause mortality compared to healthy controls. When comparing HS patients to matched psoriasis controls, HS patients had an RR of 1.31 (1.17–1.47) for myocardial infarction, 1.04 (0.93–1.16) for ischemic stroke, 1.24 (1.15–1.34) for heart failure, 1.16 (1.09–1.22) for MACEs, and 1.38 (1.27–1.5) for all-cause mortality. Herein, we demonstrate that patients with HS have increased rates of all cardiovascular diseases investigated when compared to healthy and psoriasis controls, even after adjusting for cardiovascular disease risk factors. Conclusions: These findings highlight the potential benefit in screening for and managing modifiable cardiovascular risk factors in HS patients.
Background: Pain is an undermanaged symptom of hidradenitis suppurativa (HS). Relatively few studies have investigated at-home pain management measures HS patients use, the efficacy of these measures, and how they may correlate with disease severity. Objectives: The objective of this study is to survey pain management strategies used by HS patients and evaluate their efficacy. Methods: We conducted a survey study on patients with HS from April 2023 to April 2024 at the Hidradenitis Suppurativa Clinic at Thomas Jefferson University Hospital (Philadelphia, PA). We measured the usage of certain pain management options in the past year for HS patients and asked patients to rank their pain relief from each measure on a Likert scale. We also recorded the clinically determined Hurley stage for HS severity to study correlations between the Hurley stage and pain management methods used/efficacy. Results: Surveyed patients (n = 63) indicated a preference for over-the-counter (OTC) and topical pain management measures. For higher Hurley stages, rates of cannabis or prescription pain management usage were higher. Patients with Hurley stage III reported significantly greater relief from prescription opioid and non-opioid medications when compared to oral OTC medications; however, the degree of relief was considerably less than that obtained by patients with milder disease. Conclusion: Pain management can be challenging for HS patients, especially among those with higher disease severity. Of note, altered pain pathways in HS could contribute to the reduced effect of pain relief methods in more severe stages.